Cutaneous marginal zone B-cell lymphoma in a patient previously diagnosed with cutaneous Waldenström macroglobulinemia

2010 ◽  
Vol 63 (2) ◽  
pp. e59-e61 ◽  
Author(s):  
Marsha Mitchum ◽  
Melissa Scorza ◽  
Brian Thomas ◽  
Kenneth Galeckas
Keyword(s):  
B Cell ◽  
Marginal Zone ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Waldenström Macroglobulinemia ◽  
Waldenstrom Macroglobulinemia

scholarly journals Waldenström Macroglobulinemia Caused by Extranodal Marginal Zone B-Cell Lymphoma

2001 ◽  
Vol 116 (5) ◽  
pp. 683-690 ◽  
Author(s):  
Riccardo Valdez ◽  
William G. Finn ◽  
Charles W. Ross ◽  
Timothy P. Singleton ◽  
Joseph A. Tworek ◽  
...  
Keyword(s):  
B Cell ◽  
Marginal Zone ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Waldenström Macroglobulinemia ◽  
Waldenstrom Macroglobulinemia

scholarly journals Epigenetic targeting of Waldenström macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition

Epigenomics ◽  
2020 ◽  
Author(s):  
Stephan J Matissek ◽  
Weiguo Han ◽  
Mona Karbalivand ◽  
Mohamed Sayed ◽  
Brendan M Reilly ◽  
...  
Keyword(s):  
Combination Therapy ◽  
B Cell ◽  
Histone Deacetylase ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Low Grade ◽  
Histone Deacetylase Inhibition ◽  
Waldenström Macroglobulinemia ◽  
Waldenstrom Macroglobulinemia ◽  
Bet Inhibitors

Aim: Waldenström macroglobulinemia (WM) is a low-grade B cell lymphoma characterized by overproduction of monoclonal IgM. To date, there are no therapies that provide a cure for WM patients, and therefore, it is important to explore new therapies. Little is known about the efficiency of epigenetic targeting in WM. Materials & methods: WM cells were treated with BET inhibitors (JQ-1 and I-BET-762) and venetoclax, panobinostat or ibrutinib. Results: BET inhibition reduces growth of WM cells, with little effect on survival. This finding was enhanced by combination therapy, with panobinostat (LBH589) showing the highest synergy. Conclusion: Our studies identify BET inhibitors as effective therapy for WM, and these inhibitors can be enhanced in combination with BCL2 or histone deacetylase inhibition.

Development of EBV-associated diffuse large B-cell lymphoma in Waldenström macroglobulinemia and mantle cell lymphoma

2008 ◽  
Vol 49 (8) ◽  
pp. 1618-1619 ◽  
Author(s):  
Abraham M. Varghese ◽  
Hazem Sayala ◽  
Paul A. S. Evans ◽  
Sheila J. M. O'Connor ◽  
Russell Patmore ◽  
...  
Keyword(s):  
B Cell ◽  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Waldenström Macroglobulinemia ◽  
Large B Cell Lymphoma ◽  
Waldenstrom Macroglobulinemia ◽  
Mantle Cell ◽  
Large B Cell

scholarly journals Histological transformation to diffuse large B-cell lymphoma in patients with Waldenström macroglobulinemia

2016 ◽  
Vol 91 (10) ◽  
pp. 1032-1035 ◽  
Author(s):  
Jorge J. Castillo ◽  
Joshua Gustine ◽  
Kirsten Meid ◽  
Toni Dubeau ◽  
Zachary R. Hunter ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Waldenström Macroglobulinemia ◽  
Large B Cell Lymphoma ◽  
Waldenstrom Macroglobulinemia ◽  
Histological Transformation ◽  
Large B Cell
Sign in / Sign up

Export Citation Format

Share Document